Skip to main content

Table 1 Baseline characteristics and treatment outcomes of included patients (n = 88)

From: Treatment outcomes and prognostic factors for non- malignancy associated secondary hemophagocytic lymphohistiocytosis in children

Characteristic Value
Gender (male), % 50 (56.8%)
Age, years old 1.4 (0.2–15)
Fever 88 (100%)
CMV % 13 (14.8%)
Leukocyte 3.22 (0.25–36.47)
Neutrophil 1.195 (0.05–11.86)
Platelet 67.00 (7–562)
Hemoglobin 86.5 (31–131)
Fibrinogen 1.29 (0.27–4.56)
Albumin 29.27 ± 5.61
Ferritin 3564.5 (132.0–591,123.0)
AST 249.15 (21.0–9420.0)
ALT 207.50 (8.0–4953.0)
LDH 944.5 (156.0–5311.0)
TG 3.34 (0.39–13.56)
CRP 15.05 (0.25–161.54)
GGT 207.5 (7.0–1550.0)
D-dimer 2489.0 (129.0–35,600.0)
DIC % 28 (31.8%)
Splenomegaly % 49 (55.7%)
Jaundice % 34 (38.6%)
Bone marrow involvement % 51 (58.0%)
Hepatomegaly % 65 (73.9%)
Ascites % 21 (23.9%)
Lymphadenopathy %
CR achievement after treatments
28 (31.8%)
58 (65.9%)
Therapy
 HLH94/2004based therapy 34 (38.6%)
 Steroid + IVIG 8 (9.1%)
 Steroid 22 (25%)
 Only observation 23 (26.1%)
 Hematopoietic stem cell transplantation 1 (1.1%)
Causes of HLH 56 (76.7%)
 EBV-associated 30 (33.7%)
 Immunodeficiency 6 (6.7%)
 Autoimmune disease (AID) 13 (14.6%)
 Unknown cause and infection other than EBV 40 (44.9%)
Treatment response at 8 weeks
 Early stable responder 29 (33.3%)
 Late stable responder 28 (32.2%)
 Unstable responder 17 (19.5%)
 Non-responder 13 (14.9%)
  1. Abbreviations: HLH hemophagocytic lymphohistiocytosis, AST aspartate aminotransferase, ALT alanine transferase, LDH lactate dehydrogenase, CRP C-reactive protein, DIC disseminated intravascular coagulation, EBV Epstein-Barr virus, CR complete remission, EBV Epstein-Barr virus, TG triglyceride, GGT gamma-glutamyl transpeptidase